Last 47 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -12.26 | — | 58.97 | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 144.95 | 411.47 | 13.84 | 94.33 | 98.66 | 135.85 | 84.16 | 73.94 | 49.08 | 18.25 | 20.53 | 18.31 | 14.40 |
| — | +202.9% | -83.6% | +27.6% | +101.0% | +644.4% | +309.9% | +303.8% | +240.7% | +50.7% | +190.1% | +108.3% | -53.1% | |
| P/B Ratio | 8.88 | 11.25 | 7.16 | 8.41 | 6.38 | 6.81 | 4.75 | 3.95 | 3.97 | 2.85 | 2.84 | 3.40 | 2.63 |
| — | +65.3% | +51.0% | +112.7% | +60.6% | +138.9% | +67.3% | +16.1% | +51.1% | +43.8% | +7.7% | +27.6% | +13.1% | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | 93.09 | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | 54.70 | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
Arbutus Biopharma Corporation's operating margin was -1567.7% in Q3 2025, down 1581.5 pp QoQ and up 33.5 pp YoY. The trailing four-quarter average of -1100.9% exceeds the current quarter, suggesting the latest result may reflect seasonal weakness or a one-off headwind.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 100.0% | 97.9% | 100.0% | -407.9% | -459.7% | 100.0% | 100.0% | 100.0% | -718.8% | 100.0% | 100.0% | 100.0% | -267.5% |
| — | -2.1% | 0.0% | -507.9% | +36.0% | 0.0% | 0.0% | 0.0% | -168.7% | 0.0% | 0.0% | 0.0% | +46.4% | |
| Operating Margin | -1236.7% | -1567.7% | 13.9% | -1964.7% | -885.2% | -1601.2% | -1250.5% | -1263.9% | -967.2% | -462.8% | -395.3% | -260.4% | -361.3% |
| — | +2.1% | +101.1% | -55.5% | +8.5% | -246.0% | -216.3% | -385.4% | -167.7% | -54.7% | -299.0% | -198.5% | +44.3% | |
| Net Margin | -1133.0% | -1463.5% | 23.5% | -1390.4% | -796.2% | -1472.5% | -1146.9% | -1166.8% | -900.3% | -431.6% | -367.5% | -244.3% | -351.2% |
| — | +0.6% | +102.0% | -19.2% | +11.6% | -241.2% | -212.1% | -377.5% | -156.4% | -46.2% | -268.8% | -95.0% | +47.2% |
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -68.8% | -9.7% | 3.1% | -27.8% | -12.3% | -17.2% | -16.7% | -16.2% | -17.1% | -15.8% | -12.3% | -11.6% | -15.5% |
| — | +43.8% | +118.6% | -71.5% | +28.4% | -8.6% | -36.1% | -39.2% | -10.3% | -34.5% | -37.9% | -23.8% | -9.1% | |
| ROA | -50.6% | -7.7% | 2.3% | -19.7% | -9.2% | -13.1% | -12.8% | -12.1% | -12.7% | -12.0% | -9.3% | -8.5% | -11.0% |
| — | +41.3% | +118.0% | -62.6% | +27.7% | -9.5% | -37.3% | -43.5% | -16.0% | -43.2% | -48.2% | -18.3% | +4.6% | |
| ROIC | -75.9% | -12.1% | 2.5% | -49.2% | -14.5% | -21.6% | -22.1% | -17.3% | -15.5% | -14.1% | -11.8% | -11.2% | -13.3% |
| — | +43.8% | +111.3% | -184.9% | +6.7% | -53.7% | -86.5% | -54.5% | -17.0% | -36.0% | -25.7% | -23.4% | +35.3% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
The current ratio has improved 167.9% YoY to 18.80x, strengthening the short-term liquidity position. Debt/Equity has declined for 3 consecutive quarters, reflecting a deleveraging trend.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.01 | 0.01 | 0.01 | 0.02 | 0.01 | 0.06 | 0.06 | 0.07 | 0.08 | 0.08 | 0.08 | 0.08 | 0.09 |
| — | -81.2% | -78.4% | -78.7% | -83.9% | -24.7% | -24.3% | -11.8% | -10.3% | -16.5% | -26.3% | -26.3% | -17.8% | |
| Debt / EBITDA | — | — | 0.73 | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 8.15 | 18.80 | 20.53 | 6.01 | 8.15 | 7.02 | 6.56 | 6.69 | 5.87 | 6.34 | 6.47 | 6.08 | 4.60 |
| — | +167.9% | +213.0% | -10.2% | +38.8% | +10.6% | +1.3% | +10.2% | +27.6% | +23.6% | +22.4% | +14.0% | -67.9% | |
| Quick Ratio | 8.15 | 18.80 | 20.53 | 6.01 | 8.15 | 7.02 | 6.56 | 6.69 | 5.87 | 6.34 | 6.47 | 6.08 | 4.60 |
| — | +167.9% | +213.0% | -10.2% | +38.8% | +10.6% | +1.3% | +10.2% | +27.6% | +23.6% | +22.4% | +14.0% | -67.9% | |
| Interest Coverage | -557.07 | -360.57 | 53.14 | -1237.79 | -464.43 | -739.31 | -634.79 | -440.07 | -471.52 | -468.65 | -107.51 | -87.94 | -73.02 |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 47 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare performance and metrics against top competitors.
Start ComparisonArbutus Biopharma Corporation's current P/E is -12.3x. The average P/E over the last 1 quarters is 59.0x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Arbutus Biopharma Corporation's current operating margin is -1236.7%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Arbutus Biopharma Corporation's business trajectory between earnings reports.